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1. Introduction  
Protein engineering is a process that modifies/creates functions or increases stabilities of 
proteins through artificial selection and evolution (Angeletti, 1998). For the fast 
development of molecular biology techniques, numbers of proteins have been successfully 
engineered to equip noval functions in the past several decades (Alahuhta et al., 
2008;Bottcher & Bornscheuer, ;Ehren et al., 2008;Huston et al., 1988;Leta Aboye et al., 2008). 
These engineered proteins are developed either for academic research purposes or 
biomedical applications. The core of protein engineering is an appropriate protein scaffold 
(Hey et al., 2005;Pessi et al., 1993;Skerra, 2007). An excellent protein scaffold not only 
provides a platform for developing noval functions but also has many benefits, such as cost 
reduction during development/production or lasting efficacy of protein. An suitable protein 
scaffold should equip several characteristics (Hey et al., 2005;Pessi et al., 1993;Skerra, 2007). 
To introduce tailored functions into protein scaffolds is a major challenge and has a unique 
significance in protein design (Hey et al., 2005;Pessi et al., 1993). 
A protein scaffold is a peptide framework that exhibits a high tolerance of its fold for 
modifications (Hey et al., 2005). Candidates for suitable protein scaffolds should exhibit a 
compact and structurally rigid core. The folding properties of the protein scaffolds should 
not be significantly changed when the side chains in a contiguous surface region are 
replaced or loops of varying sequence and length are presented (Skerra, 2007). Several 
additional priorities have to be considered if the scaffold is used in biomedical 
applications. The scaffold must display extra stabilities to environments, such as low pH, 
high concentration of chaotropic agents and high temperatures. Molecular weight of the 
scaffold should be low and small molecules have advantages in passing tissue barrier 
(Baines & Colas, 2006). The scaffold should highly resist protease degradation and this 
ensures the engineered proteins can be safe in the gastrointestinal tract and not degraded 
(Aharoni et al., 2005). Low immunogenecity is important to reduce unexpected side 
effects and damage of healthy tissue (Van Walle et al., 2007). Post-translational 
modification of protein is an important issue, too. Most of eukarytic proteins require post-
translationally modified then gain their functions. These modifications includ 
glycosylation, cleavage of pre-peptide, formation of disulphide bridge and association of 
multiple peptides. Appropriate glycosylation also could reduce immunogenicity of 
proteins (Kosloski et al., 2009;Wang et al., 2010;Wu et al.). Currently, bacterial cells are the 
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most conventional and convenious tools for mass production of recombinant proteins,  
but it is not easy for bacterial cells to undergo post-translational modication of eukaryotic 
proteins (Jacobs & Callewaert, 2009;Muir et al., 2009). Even expressed in eukaryotic cells,  
glycosylation of proteins is not exactly the same among difference specises (Perego  
et al., 2010). Unappropriatly modified recombinant proteins might lead to unexpected 
immune respones, if the proteins are used for medical purpose (Kosloski et al., 2009; Li & 
d'Anjou, 2009). 
Protein designing challenges our understanding of the principles underlying protein 
structure and is also a good method to access our understanding of sequence-structure and 
structure-function relationship (Nikkhah et al., 2006). Rational design of proteins requires 
detailed knowledge of protein folding, structure, function, and dynamics (Chen et al., 2005). 
To build expression libraries, it is necessary to understand a protein scaffold in detail to 
amino acids usage on each residue position. This would reveal the key elements that affect 
functions and stabilities of a protein scaffold. 
The appearance of new intellectual property, the breakthroughs in technology, or the 
increase in a market need are three major impacts to biopharma industry. Protein 
engineering is a branch of the biopharm industry, where intellectual property rights 
apparently play the most important role in the development and commercialization of 
final products. The intellectual property strategy to protect inventions of biopharma 
industry is to patent and to license them on an exclusive basis. The intellectual property 
also must be included in the linkage of research/development and business to ensure the 
commercial viability of biopharma products and to cope with the rapid changes of 
market. Currently, the intellectual property situation of biopharma industry is too 
complex and hampers the generation and production of recombinant protein/peptide 
drugs. Pantent analysis and patent map are necessary and helpful while planing the 
research and development and marketing. A well planed intellectual property strategy 
can not only protect the output of research and development but also defend market. A 
protein scaffold with simple legal situation will avoid knotty lawsuits. In recent years, 
shouts for alternative protein scaffolds is urgent and alternative protein scaffolds usually 
provide a favourable intellectual property situation. In this chapter, we will focus on a 
protein scaffold, cysteine-stabilized α/β (CSαβ) motif, and discuss protein engineering 
based on the scaffold. 
2. Cysteine-stabilized α/β motif 
2.1 Specific pattern and structural feature 
CSαβ motif is a very unique protien scaffold. Proteins with a CSαβ motif express a high 
diversity in their protein primary structures (Figure 1) but share a common core sturcture 
that consists of a α-helix and an anti-parallel triple-stranded β-sheet (Figure 2 a to d). This is 
especially interesting not only for academic research but also very useful for applied 
utilities. From the protein sequence alignment analysis, six cysteines and one glycine (-C-Xl-
CXXXC-Xm-GXC-Xn-CXC-) are exzactly conserved in all proteins containing a CSαβ motif 
(Carvalho & Gomes, 2009;Lay & Anderson, 2005). The cysteines form a framework and 
tightly connect the intramolecular structures. The most significant feature of the framework 
is two disulphide bonds which are formed with a patten of (i, i+4) and (j, j+1). The cysteines 
of (i, i+4) and (j, j+1) are located in the α-helix and the β3 strand of the β sheet; respectively 
(Figure 1). The helix and the sheet are connected by the disulphide bonds pairing with the 
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pattern (i, i+4) and (j, j+1) (Assadi-Porter et al., 2000;Fant et al., 1999;Sun et al., 2002;Zasloff, 
2002;Zhu et al., 2005). The third disulphide bond connects loop 1 and and β2 strand. In the 
β2 strand one glycin is conserved and locates in the central region of the motif. In plant 
defensins, there is usually a forth disulphide bond that seal the N- and C- terminee. The 
positively charged α-helix is another character. The positively charged residues are 
especially concentrated in the helix. β-sheet of the motif is formed by a hydrophobic amino 
acid clust and the sheet is composed by two or three anti-parallal strands. Loop regions of 
the mofit are highly diversed in lenght among proteins. There is a small turn that connects 
the helix and β2 strand. 
 
 
 
Fig. 1. The sequence alignment of proteins containing CSαβ motif. Sequences of two 
scorpion toxins (UniProt P13487, P0C5H3), two plant defensins (UniProt P56552, B6DX36), 
two insect defensins (UniProt P10891, Q38LE8) and two mollusk defensins (UniProt P85008, 
C4NY93) are aligned. The restrictly conservered residures, include six cysteins and one 
glycin, are high lighted in red. The green arrow box, red box and cyan boxs above the 
alignment represent β strands, α-helix and loops; respectively. The blue lines above on the 
top indcate the disulphide bond bwteen cysteines.  
2.2 Biological distribution and functions 
To date, there are at least four hundred proteins with a CSαβ motif have been discovered 
and deposited in databases. Proteins with the motif are widely distributed among plants, 
insects, arachnidia and mollusca (Sun et al., 2002;Zhu et al., 2005). They exhibit a wide 
spectrum of biological activities, including antimicrobial activity, enzyme inhibitory 
function, inhibition of protein translation and sweet taste (Assadi-Porter et al., 2000;Chen et 
al., 2005;Clauss & Mitchell-Olds, 2004;Spelbrink et al., 2004;Stec., 2006;Wong & Ng, 
2005;Zhu et al., 2002). Proteins with the CSαβ motif usually serve a common function as 
defenders of their hosts (Lobo et al., 2007;Song et al., 2005;Zasloff, 2002).  
Before designing a unique function into a protein scaffold, it is important to understand the 
relationship between each part of the scaffold and its biological function. Based on the three-
dimenional structure, protein scaffold containing a CSαβ motif can be devided into three 
parts: one α-helix, one β-sheet and three loops. It is well known that the three parts bearing 
different biological functions (Liu et al., 2006;Thevissen et al., 1996;Wong & Ng, 2005;Zhao et 
al., 2002). 
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(a) The core structure of CSαβ motif.   (b) Mosquito defensin (UniProt ID: Q17027) 
  
(c) Wheat defensin (UniProt ID: P20158). (d) Scorpion toxin (UniProt ID: P13487) 
Fig. 2. The core structure and three dimensional structrues of different specices. The 
structures are presented in color ribbon. Red: α-helix, green: β-sheet, and cyan: loop. 
Protein structures are retreved from Protein Data Bank and visualized with PyMol 
0.99rc6.  
The α-helix is related to antimicrobial ability. As described previously, the helix forms a 
positively charged cluster. When the positively charged residues were replaced with null or 
negatively charged amino acids, the anti-microbial ability of the proten is also changed. For 
its net positive charge, it is believed that proteins with the motif could interact with 
negatively charged cell membrane (Thevissen et al., 1996;Thomma et al., 2003). Several 
studies have demostrated that plant defensins are able to pass artificial membranes and lead 
to ions leaking from one side of the membrane. The mechanism about how plant defensin 
passing membrane is not revealed, yet. 
Role of the β-sheet is less studied and disscussed. The direct mutagensis studies showed 
when the hydrophobic residues in the β-sheet are alanine substituted, biological function of 
mutated proteins are dromatically reduced (Walters et al., 2009;Yang et al., 2009). The 
maximal effects of mutated proteins are only 30-40% maximal effects of  the wild type, even 
at a high protein concentration. Protein-protein docking model showed that the β-sheet 
could form interaction interface with their counterpart. These data imply that, the 
distribution of the hydrophobilc residues in the β-sheet plays a role in protein-protein 
interactions and β-sheet could relate to the protein-protein interaction specificity to their 
targets. 
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The length of loop regions are different from protein to protein and the loops connecting 
CSαβ motif can serve as functional epitopes (Figure 3) (Lay & Anderson, 2005;Wijaya et al., 
2000;Zhao et al., 2002). For example, loop 1 of the Arabidopsis thaliana trypsin inhibitor 
(ATTp) and loop 2 of cowpea thionine are the functional epitopes for trypsin inhibition 
(Wijaya et al., 2000;Zhao et al., 2002). The loop 3 of Vigna radiate defensin 1 (VrD1) is the 
functional loop for insect α-amylase inhibition (Lin et al., 2007;Liu et al., 2006).  
 
 
Fig. 3. Structure-function relationship of peptide with a CSαβ motif. Red: α-helix, green: β 
strands, and cyan: loops. 
2.3 Structural ultra-stability 
A protein scaffold with ultra high stability can maintain its three dimensional structure in 
extreme environments and its functions can be preserved. Therefore, when a protein 
scaffold applied in biomedical applications, its structural stabilities must be considered. The 
scaffold should be able to pass a low pH environment in the stomach, resist protease 
digestion, endure chaotropic agents at high concentrations and so on. These criteria are to 
ensure the engineered proteins could reach their target sites and perform functions inside 
body, and are not destroyed. It has been reported that proteins with a CSαβ motif equip 
ultra stabilities to several extreme environments such as urea at a concentration of 6M, a 
temperature over than 95°C, and resist protease digestion without changing its structure 
(Malavasic et al., 1996;Yang et al., 2009). In Table 1, the properties of CSαβ motif and single-
domain antibody are listed and compared (Holt et al., 2003;Skerra, 2007;Yang et al., 
2009;Yang & Lyu, 2008). For their advantages, such as high specificity and affinity, 
antibodies still are the most popular protein scaffold for engineering. Antibodies are widely 
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used both in routine laboratorial experiments and clinical diagnosis. In spite of their 
significant clinical success, several disadvantages, including high cost in manufacturing, 
large in size, undesired effector functions and complex intellectual property situations, 
obstruct their development and applications (Jones et al., 2008). Single-domain antibody is 
only constituted of antibody variable regions and does not have constant regions (Holt et al., 
2003). Compared with single-domain antibodies, the proteins with a CSαβ motif have 
smaller molecular weights and higher structural stabilities (Holt et al., 2003;Skerra, 
2007;Yang et al., 2009). As previously described, proteins with a CSαβ motif share low 
sequence identity but high structural similarity (Lin et al., 2007). Their functions are highly 
varied and sturctures are ultra-stable. There is a possibility to utilize CSαβ motif as an 
engineering scaffold for biomedical applications (Yang & Lyu, 2008). 
 
Item 
Molecule 
Single-domain antibody CSαβ motif protein 
Molecular weight 11-15 kDa 5-7 kDa 
Generation of expression library B cell mRNA Synthetic 
Water solubility Less High 
Ultra stability 
Unfolded 6M Gdn-HCl
Tm 60-78°C 
Ultra stable 6M Gdn-HCl 
Tm > 96°C 
Post-translational modification Glycosylation Disulfide bridge 
High functional diversity Yes Yes 
Tolerate to amino acid substitution Loop regions Structural and loop regions 
Enzyme inhibition Not certain Direct inhibition 
Membrane binding Not certain Direct binding 
Legal problem Very complex Simple 
Table 1. Comparison of properties bwtween CSαβ motif and single-domain antibody. 
2.4 Amino acid usage of CSαβ motif 
To understand the amino acid usage of a protein scaffold can reveal relationships among 
structures, functions and sequence residues (Kristensen et al., 1997;Yang et al., 2009). To 
completely understand the relationships could be an approach through extensive amino 
acid substitution and analysis of protein sequences (Corzo et al., 2007;Wang et al., 2006). 
Amino acid substitution have been performed in plant defensins, brazzein of Pentadiplandra 
brazzeana and VrD1 of Vigna radiate, and some key residue positions are discovered (Assadi-
Porter et al., 2010;Yang et al., 2009). In both cases, amino acid substitution does not lead to 
the structure significantly being changed in all positions along the sequence but the 
replacement in some positions have effects on biochemical function (Assadi-Porter et al., 
2010;Yang et al., 2009). 
It has been noted that certain amino acids have preference to fold into a given secondary 
structure (Chan et al., 1995;Zhong & Johnson, 1992). Comprehending preference of amino 
acids usage will be really helpful to protein engineering and can be as a fundment for 
designing innovative peptides. The two major classes of CSαβ motif protein are plant 
defensins and scorpion toxins (Zhu et al., 2005). Currently, there are at least 140 sequences of 
scorpion toxin and 180 sequences of plant defensin deposited in the SwissProt database and 
the numbers are continuely increased. The peptide sequences of the scorpion toxin and 
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plant defensin peptides deposited in the SwissProt database are retrieved and amino acid 
usage perferacnes are separately analyzed (Table 2 and Table 3).  
In Table 2 and Table 3, the twenty amino acids are listed on the top row, the secondary 
structures and residue positions are listed on the left two columns. Use of amino acids in 
each position is counted and the usage frequency is calculated (form 0.00 to 1.00). Amino 
acids with a high usage frequency (> 0.20) are listed on the right column. The results are 
interesting and different between scorpion toxins and plant defensins. In scorpion toxins, 
peptides tend to employ similar amino acids in the same position. Therefore, sequences of 
scorpion toxins are less diverse and more uniformed. In plant defensins, sequences of 
peptides are more diverse. The major targets of scorpion toxins are ion channels on the 
neuron cell surface but the targets of plant defensins are various form peptide to peptide 
(Zhu et al., 2005). This might be the reason for the amino acid usage difference between the 
two classes of CSαβ motif peptides. In the helix region, scorpion toxins prefer using charged 
residues and plant defensins are more inclusive of different type of amino acids. The most 
interesting is the two residues flanking the exzactly conserved glycine on β22. In scorpion 
toxins, two tyrosins are prefered on β21 and β23, and the rates are 0.44 and 0.75; respectively. 
In plant defensins, a preceded glycine (β21) is prefered to the glycine on β22 and the 
frequency is 0.35. It is worth to clarify the role of the two tyrosins surrounding the glycine 
on β22 of scorpion toxins. Although the frequnectly used amino acids are listed, it just 
provides a reference for protein designing and there is no necessarity that combination of 
these amino acids forms a universal sequence. 
 
 Position 
Amino acids High 
 frequencya A G V L I F Y W C S T D E N Q R H K M P 
S
tr
an
d
 1
 
S1 0.81 0.12 0.03 G 
S2 (C)         1.00            C 
S3 0.05  0.03  0.01      0.03     0.02  0.85   K 
S4   0.34 0.13 0.10 0.03 0.22     0.02 0.01 0.02  0.10   0.03  V Y 
S5 0.05 0.07 0.02 0.00 0.06 0.04 0.51 0.06 0.03 0.03 0.02 0.02 0.05 0.01 S 
H
el
ix
 
H1 0.04 0.16 0.08 0.04 0.03 0.05 0.20 0.01 0.06 0.03 0.06 0.16 0.07 E 
H2  0.13  0.01 0.00 0.16 0.37 0.03  0.10  0.03 0.03 0.05 0.08  0.01    Y 
H3 (C)         1.00            C 
H4 0.09 0.05 0.03 0.05 0.10  0.01    0.01 0.25 0.06 0.22 0.03 0.03  0.03 0.01 0.01 D E 
H5 0.01 0.01 0.01 0.01 0.01     0.09 0.09 0.14 0.03 0.17 0.04 0.07 0.01 0.30  0.01 K 
H6 0.01  0.09 0.08 0.07 0.01   0.03 0.01 0.01 0.01 0.43 0.02 0.02  0.13 0.01 0.02 0.07 E 
H7 (C)         1.00            C 
H8 0.03 0.03 0.01 0.01      0.09 0.02  0.03 0.01 0.07 0.11 0.01 0.57   K 
H9 0.22 0.05 0.03 0.11 0.03 0.01 0.02 0.06 0.01 0.14 0.04 0.01 0.09 0.16 0.01 A 
β 2 
st
ra
n
d
 
β21 0.01 0.04 0.01 0.01 0.09 0.44 0.13 0.02 0.15 0.02 0.01 0.01 0.05 Y 
β22 (G)  1.00                   G 
β23     0.01 0.02 0.75   0.01 0.03 0.01 0.02  0.01 0.01 0.01 0.11   Y 
β24 (C)         1.00            C 
β25 0.01 0.01 0.01 0.02 0.34 0.26 0.00 0.03 0.01 0.03 0.01 0.00 0.01 0.10 0.01 0.07 Y W 
β 3 
st
ra
n
d
 
β31 0.49 0.05 0.03 0.00 0.01 0.01 0.05 0.01 0.01 0.02 0.00 0.04 0.02 0.01 0.25 A K 
β32 (C)         1.00            C 
β33 0.01   0.01 0.01 0.01 0.28 0.45    0.02  0.01 0.01  0.05 0.14 0.01  W Y 
β34 (C)         1.00            C 
β35 0.04 0.07  0.01 0.03 0.01 0.22 0.00  0.02 0.07 0.01 0.42 0.01 0.05   0.05 0.01  E Y 
Table 2. The high frequent amino acids in the structural regions of scorpion β toxin. 
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Position 
Amino acids 
High 
 frequencya 
A G V L I F Y W C S T D E N Q R H K M P  
S
tr
an
d
 1
 
S1 0.02 0.08 0.20 0.07 0.01 0.03 0.01 0.27 0.02 0.08 0.01 0.02 0.07 0.01 0.04 0.04 0.02 T L 
S2 (C)         1.00            C 
S3 0.01  0.04 0.07 0.02 0.02 0.02 0.01  0.05 0.03 0.05 0.34 0.01 0.04 0.08 0.04 0.11 0.07 0.01 E 
S4 0.06 0.02 0.07 0.05 0.03     0.18 0.10 0.04 0.07 0.08 0.02 0.13 0.03 0.12  0.01  
S5 0.05 0.04 0.05 0.12 0.05 0.01 0.04 0.06 0.05 0.03 0.07 0.00 0.12 0.08 0.01 0.08 0.01 0.13 
H
el
ix
 
H1 0.07 0.10 0.02 0.01 0.02 0.01 0.01 0.15 0.15 0.05 0.03 0.14 0.05 0.06 0.04 0.08 0.04 
H2 0.12 0.04 0.01 0.08 0.02 0.02 0.00 0.02  0.07 0.05 0.11 0.05 0.27 0.02 0.02 0.03 0.06 0.01 0.03 N 
H3 (C)         1.00            C 
H4 0.24 0.03 0.04 0.02 0.02 0.00 0.03   0.06 0.02 0.17 0.03 0.08 0.02 0.09  0.19   A 
H5 0.06 0.01 0.02 0.04 0.02 0.03  0.01  0.11 0.08 0.09 0.06 0.23 0.09 0.03 0.04 0.10  0.01 N 
H6 0.05 0.01 0.25 0.06 0.01 0.01 0.04  0.02 0.08 0.05 0.01 0.05 0.05 0.16 0.01 0.11 0.02 0.03 0.02 V 
H7 (C)         1.00            C 
H8 0.03 0.01 0.04 0.11 0.18 0.02 0.03 0.01  0.01 0.04 0.01 0.01 0.02 0.09 0.18 0.05 0.16 0.03 0.02  
H9 0.06 0.02 0.01 0.01 0.01 0.01 0.09 0.21 0.02 0.07 0.19 0.11 0.08 0.01 0.10 0.01 0.02 T 
β 2 
st
ra
n
d
 β21 0.05 0.35 0.05 0.01 0.02 0.01 0.01 0.01 0.11 0.03 0.08 0.02 0.05 0.01 0.05 0.14 0.05 G β22 (G)  1.00                   G 
β23 0.04 0.02 0.05 0.01 0.01 0.05 0.06   0.18 0.07 0.05 0.06 0.07 0.03 0.11 0.06 0.17 0.01   
β24 (C)         1.00            C 
β25 0.02 0.01 0.07 0.05 0.06 0.04 0.01 0.01 0.06 0.02 0.14 0.04 0.17 0.03 0.16 0.09 0.06 0.01 0.01 
β 3 
st
ra
n
d
 β31 0.05 0.02 0.02 0.07 0.02 0.02 0.04 0.05 0.01 0.02 0.04 0.06 0.30 0.04 0.23 0.05 K β32 (C)         1.00           C 
β33 0.01 0.02 0.07 0.12 0.15 0.19 0.13 0.07   0.02 0.02 0.03 0.01 0.01 0.03 0.05 0.05 0.05  
β34 (C)         1.00           C 
β35 0.02 0.02 0.03 0.04 0.06 0.02 0.22 0.04 0.07 0.30 0.03 0.02 0.03 0.04 0.04 0.01 0.04 0.02 Y 
Table 3. The high frequent amino acids in the structural regions of plant defensin. 
3. Applications of CSαβ motif peptides 
Human beings have been using natural products containing CSαβ motif peptides for several 
hundreds years. The most well known natural products are sweet peptides of plants and 
scorpion venom. For their anti-microbial and pesticide abilities, in many cases, peptides 
with CSαβ motif are transfected into industrial crops to protect these transgenic plant from 
pathogens. In recent years, some of plant defensins are also screened and selected as 
antibiotics for therapeutic utilities. In this section, some peptides with therapeutic potential 
are selected and discussed. 
3.1 Sweet peptide: Brazzein 
Brazzein is isolated from Pentadiplandra brazzeana, a climbing plant plant of the West Africa. 
Berry fruits of Pentadiplandra brazzeana have sweetness and are traditional foods of African 
natives (Assadi-Porter et al., 2008;Yang & Lyu, 2008). For a long time, the sweetness of the 
berry fruits is a secret. Ding and Hellekant at University Wisconsin Madison isolated a small 
peptide with sweetness from Pentadiplandra brazzeana and named it as brazzein 1994 (Ming 
& Hellekant, 1994). Peptide sequence analysis shows that brazzein contains a set of (i, i+4) 
and (j, j+1) cysteine pattern. Its NMR structure is solved and confirms it as a CSαβ motif 
peptide 1998 (Caldwell et al., 1998). Brazzein is the smallest, most heat-stable and pH-stable 
protein known to have an intrinsic sweetness (Jin et al., 2006). Brazzein is 200 times sweeter 
than sugar and it can be used both in cold and hot drinks/foods without change its sweet 
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taste (Jin et al., 2006). Brazzein is widely recurited as sugar substitute in low caloric dietary 
formulas or for diabetes patients. Brazzein is a food additive for several years and no side 
effects have been reported (Yang & Lyu, 2008).  
3.2 Scorpion venom: Traditional remedies 
Scorpion is therapeutically used in traditional Chinese medicine for hundreds of years. 
Figure 4 shows the therapeutic instruction of using scorpion described in the Compendium of 
Materia Medica, an ancient Chinese pharmacopoeia compiled in the 1500s AD. In traditional 
Chinese medicine, scorpion is recruited as one of the major treatments for stroke, 
rheumatism, epilepsy, hemiplegia, convulsions, cramps, twitchs, headaches, tetanus and 
scrofula. Buthus martensii Karsch is the most common species of scorpion that are processed 
as traditional Chinese medicine. Captured scorpions have to be preserved in salt. The 
preserved scorpions are usually boiled with herbs, such as licorice, to reduce toxicity after 
washing off the salt. Patients take the boiled extracts twice daily and the amount of 
scorpions should be controlled to under 10 grams for an adult daily. Most of proteins will be 
denatured and loss functions after being exposed to salt at a high concentration and water 
boiling temperature. The major effective composition of scorpion is scorpion venom. It has 
been demonstrated the venom can block cation channel of insects (Li et al., 2000;Wang et al., 
2001). Several peptides containing CSαβ motif have been isolated from scorpion venom. The 
peptides can keep their structures and functions after be exposed to water boiling 
temperature and solvents of high salt concentration. BmK AEP, a peptide containing a CSαβ 
motif isolated from Buthus martensii Karsch venom, is the first anticonvulsant purified in the 
venom (Wang et al., 2001). BmK AEP has inhibitory effect to coriaria lactone-induced 
epilepsy model in rodents. It has a low toxicity to mice in doses up to 20 mg/animal 
(Rajendra et al., 2004). There is nearly no effect on heart rate, electroencephalogram, 
breathing rate and blood pressure (Rajendra et al., 2004;Wang et al., 2001). CII9, another 
peptide with a CSαβ motif isolated from Centruroides limpidus Karsch, can partially inhibit  
 
 
Fig. 4. The therapeutic instruction of scorpion described in the ancient Chinese 
pharmacopoeia: Compendium of Materia Medica. 
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sodium ion currents from superior cervical ganglion neurons of rats (Dehesa-Davila et al., 
1996;Possani et al., 1999). In the rat model, CII9 also exerts a depressant effect on the 
behavior and electroencephalographic activity and antagonizes the epileptiform activity 
induced by penicillin (Dehesa-Davila et al., 1996;Gazarian et al., 2005;Possani et al., 1999). 
3.3 Peptide antibiotics: Plectasin  
Peptides with a CSαβ motif act as primary defenders for their host. Microbe-killing 
abilities of plant defensins have been demonstrated and transgenic industrial crops have 
been bred to carry specific defensins to increase their tolerance to plant pathogens. For 
directly binding to membranes or cell walls, target pathogens do not easily resist peptides 
with a CSαβ motif as they do to protein-targeting antibiotics. Pathogenic microbes would 
escape attacking from conventional antibiotics by mutating proteins but it is never easy to 
change the properties of cell membranes or cell walls. Scaffold of a CSαβ motif could be as 
a suitable platform for developing peptide antibiotics. Some plant defensins are tested 
and show activities againt human pathogenic microbes. For example, Rs-AFP2, a defensin 
isolated from seeds of Raphanus sativus, has an inhibitory activity against Candida albicans 
(Landon et al., 2004;Terras et al., 1992;Thomma et al., 2003). Scientists of Novozymes, a 
Dnaish biotech company, isolated a novel plant defensin, plectasin, with excellent 
antibiotics ability. 
Plectasin is a 40-amino acid residue peptide isolated from saprophytic ascomycete, 
Pseudoplectania nigrella, and might be the first plant defensin with a CSαβ motif isolated 
from fungus (Mygind et al., 2005). Plectasin expresses anti-bacterial activities against a 
broad Gram-positive bacteria and has an inhibitory effect at a low concentration of 0.25 
µg/ml to growth of Streptococcus pneumoniae (Mygind et al., 2005). Plectasin also has a 
comparable killing rate to Streptococcus pneumoniae as do conventional antibiotics (Mygind 
et al., 2005). Streptococcus pneumoniae is a major pathogenic bacteria and the most common 
cause of hospital/community-acquired pneumonia, bacterial meningitis, bacteremia, 
sinusitis, septic arthritis, osteomyelitis, peritonitis, and endocarditis (Whitney et al., 2000). 
Currently, antibiotics are major treatments to patients with infection of Streptococcus 
pneumoniae. In recent years, Streptococcus pneumoniae is more and more resistant to 
antibiotics and the demand for new drugs to cure Streptococcus pneumoniae infection is 
urgent (Baquero et al., 1991;Whitney et al., 2000). Another challenge of theraping 
Streptococcus infection is that Streptococcus can be an intracellular pathogen and avoids 
targeting by the immune system or drugs (Gordon et al., 2000;Talbot et al., 1996). 
Different from the conventional antibiotics, plectasin can directly act on the cell wall 
precursor lipid II of Streptococcus (Mygind et al., 2005). Studies also showed that plectasin 
has an intracellular activity against Streptococcus aureus both in human monocytes and in 
mouse peritonitis model without effecting the cells viability or inducing IL-8 production 
(Brinch et al., 2009;Hara et al., 2008).  
4. Protein engineering based on CSαβ motif scaffold 
Based on the scaffold, some CSαβ proteins have been engineered to exhibit new functions or 
changing of antimicrobial activities (Lin et al., 2007;Vita et al., 1999;Vita et al., 1995). 
Different approaches, including minimal residue substitution, functional epitope exchange, 
structural based modification and combinatorial chemistry have been employed to engineer 
the scaffold to exhibit new functions (Lin et al., 2007;Thevissen et al., 2007;Van Gaal et al., 
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2004;Vita et al., 1999;Vita et al., 1995;Zhao et al., 2004). Protein structure is important to the 
rational design of a protein scaffold. It does not only reveal the shape of a protein molecule 
but sidechain orientation of each residue. This information is crucial for investigating 
possible interactions between designed protein and its target.  
4.1 Site-direct mutagenesis  
In some studies, researchers focus on the relationships of structures, functions and each 
residue of peptides with a CSαβ motif. Extensive residue substitution is usually performed 
on the peptides and the changes of structures and functions are observed. The process is 
time-consuming and labor intensive but it is required for collecting basic information about 
the scaffold. Amino acid substitution has been extensively performed on two peptides with 
a CSαβ motif, VrD1 and brazzein (Assadi-Porter et al., 2010;Yang et al., 2009). In the two 
studies, molecular docking models are also established to investigate the interactions 
between receptors and ligands.  
In both cases, similar positions along the structures are discovered that are crucial to 
functions of both peptides (Figure 5). These sites are widely distributed on β1 strand, loop 1, 
loop 2 and loop 3 (Assadi-Porter et al., 2000;Walters et al., 2009;Yang et al., 2009). From the 
molecular docking models, these sites either directly interact with their targets or play as 
functional epitopes and insert into the active site of their targets (Assadi-Porter et al., 
2010;Liu et al., 2006;Yang et al., 2009). It is interesting that, when two negatively charged 
residues, D29 and E41, of brazzein are replaced by a positively charged amino acid, the 
sweetness of brazzein is greatly improved (Assadi-Porter et al., 2010). The mutants should 
be with high interests to industrial utilities. In the case of VrD1, there is no functional 
improvement observed on its mutants (Yang et al., 2009). Comparing conformations of the 
wild-type proteins and their mutations, there are only minimal shifts measured (Assadi-
Porter et al., 2010). This implies that structure of peptide with a CSαβ motif is relatively 
stable and has high tolerance to amino acid substitution. Side chains of these residues on the 
interactive surface are crucial to biological functions of the peptides.  
 
 
Fig. 5. Superposition of brazzein and VrD1. Some critical residues are overlapping between 
brazzein and VrD1. Red: brazzein, cyan: VrD1. Red and cyan labeled residues: critical 
residues of brazzein and VrD1; respectively. The two structures are aligned with SARST 
(http://sarst.life.nthu.edu.tw/iSARST/). 
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Multiple mutation also has been performed on the scaffold. Vital et al performed minimal 
residue substitutions on the charybodotxin (Chtx), an scorpion toxin containing CSαβ motif, 
to equip metal ion binding ability (Vita et al., 1995). Three residues, K27, M28 and R34, on 
the β sheet are substituted with histidines. The modified protein exhibts a chelatine property 
but has the same circular dichroism spectrum profile as the native Chtx does.  
4.2 Functional epitope exchange 
Grafting epitopes with known function is a straightforward stratage for a protein to gain 
new function. Functional epitopes could be exchanged between proteins have a high 
sequence identity or share a high structural similarity. Based on the structural homologous, 
the β2-β3 hairpin of scyllatoxin, a scorpion toxin containing the CSαβ motif, is replaced by 
the CDR2-like loop of human CD4. The chimeric protein can bind to the HIV-1 envelope 
glycoprotein and the affinity is increased 100 fold as compared with the native scyllatoxin 
(Vita et al., 1999). In another case, VrD1 and VrD2, two defensins of Vigna radiate, share 80% 
sequence identities. The major difference of sequences concentrats on the loop 3.  When the 
loop 3 of VrD1 is grafted to VrD2, the chimeric peptide  exhibits the enzyme inhibitory 
function as VrD1 does (Lin et al., 2007). 
4.3 Combinatorial chemistry approach 
Combinatorial chemistry approach are powerful in screening and selecting binders with 
high affinity and high specificity (Hosse et al., 2006). It has been widely applied in antibody 
scaffold and thousands of antibodies are generated through the technology. Combinatorial 
chemistry approach also has been recruited to develop and isolate artificial proteins with 
new functions (Zhao et al., 2004).  The approach could accelerate protein engineering based 
on a CSαβ motif to develop novel peptides with biomedical interesting (Thevissen et al., 
2007;Van Gaal et al., 2004). Based on scaffold of insect defensin A, an expression library of 
peptides with 29 residues is constructed and used in screeening novel binders to targets.  
The expression library is artificially synthesized and amino acid of seven positions on the 
loops are randomized (Zhao et al., 2004). Tumor necrosis factor α (TNF-α), TNF receptor 1, 
TNF receptor 2 and antibody against BMP-2 are selected as targets and the screening results 
show significant enrichment in all cases. 
5. The challenges of engineering of CSαβ motif 
Although several successful engineered peptides based on the CSαβ motif scaffold have 
been reported, to design new functions into the scaffold does perplex us. In this section, we 
would like to discuss challenges in engineering a CSαβ motif to equip desired functions. 
5.1 Lacking co-structural model 
To introduce tailored functions into a protein scaffold is never an easy task. For its ultra 
stability and high diversity of function, there is no doubt that peptide with a CSαβ motif is a 
suitable scaffold to be engineered for biomedical applications. To date, there are only a few 
of successful cases are reported. Many structures of peptides with CSαβ motif have been 
solved and deposited in database, but knowledge about the motif is poor. In spite of 
hundreds of peptides with a CSαβ motif deposited in the database, it is hard to make 
conclusions relating to structures and biochemical functions of the motif. Key residues are 
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revealed in some peptides with a CSαβ motif and molecular docking models provide 
reasonable explainations (Figure 6). The real interaction is not clarified, for lacking of a co-
structural model. A co-structural model of the motif and its target will provide information 
about the dynamic interactions of the two protein molecules (Dumas et al., 2004;Thioulouse 
& Lobry, 1995). Structures of the complexes of peptides with a CSαβ motif and its 
counterparts will provide the situation of protein-protein interaction and have a great 
benefit to engineering of the scaffold. 
 
 
               (a) HIV reverse trascriptase with inhibitor     (b) Docking model 
Fig. 6. Docking model of plant defensin to HIV reverse transcriptase. Structures of HIV 
reverse transcriptase (3DRP, HIV RTase) and VrD2 (2GL1) are retrieved from the Protein 
data bank. Molecular docking is performed with PatchDock 
(http://bioinfo3d.cs.tau.ac.il/PatchDock/). (a) The crystal structure of HIV RTase with 
inhibitor. (b) Molecular docking model of VrD2 and HIV RTase. Cyan: HIV RTase, yellow: 
VrD2 and red: HIV RTase inhibitor. 
5.2 Generation of gene library and construction of expression system 
The advantages of combinatorial chemistry approach to protein engineering is its ability to 
associate every protein with its genetic material (Weng & DeLisi, 2002). There are two core 
parts about applying combinatorial chemistry approach in protein engineering: display 
techniques and gene expression library. These two core parts are equally important and 
affect each other. To date, several display techniques have been developed (Table 4) 
(Daugherty, 2007;Gronwall & Stahl, 2009). Natural properties of peptides with a CSαβ motif 
are as defenders for their native hosts and most of the peptides express anti-bacterial 
abilities, virus inhibitory abilities and inhibition of protein translation. How to design a 
expression library based on a CSαβ motif scaffold is a tough task. 
 
Technique Library limitation Expression system Disulphide bond 
Bacterial display 1011 Circular No 
Phage display 1011 Circular No 
Ribosome display 1014 Circular/Linear Yes 
Table 4. Comparison of three display techniques. 
Peptides with a CSαβ motif are tightly held by disulphide bridges and may be not easily 
folded into appropriate structures inside bacterial cells (Villemagne et al., 2006). Ribosomal 
display technique can overcome the problems (Figure 7), but it requirs an ultra clean  
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Fig. 7. Concept of ribosome display techniques. (a) expression system, (b) & (c) transcription, 
translation and folding while translation, (d) binding and selection, (e) isolation of mRNA 
from the complex, (f) reverse transcription and construction of expression system for next 
cycle of selection. A specific holder gene usually is constructed to the expression system. 
The holder can arrest protein translation and the nascent peptide can form a stable complex 
with ribomsome. 
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environment to protect mRNA from degradation (Fennell et al., 2010;Villemagne et al., 
2006). The gene library of a CSαβ motif has to be artificially synthesized then constructed to 
the expression system. There are two key issues of the synthesized gene library have to be 
considered, one is the size of library the other one is how many random residue positions it 
should have (Gronwall & Stahl, 2009;Michel-Reydellet et al., 2005). These two questions are 
hard to answer. A large library with more randomized residue positions could have more 
genotypes/phenotypes but it also has a high possibility to generate nonsense genes for the 
unvoided stop codon on unexpected positions. A library with a randomized loop 3 of a 
CSαβ motif scaffold has been constructed and successfully used in a noval binder to human 
TNF-α (Zhao et al., 2004). It also has been reported that all three loops of peptides with a 
CSαβ motif can equip unique functions and the structural regions also fine regulate the 
functions of the peptides (Assadi-Porter et al., 2010;Liu et al., 2006;Yang et al., 2009;Zhao et 
al., 2002). For a library of long length artificial genes, several cycles of PCR overlapping 
extensions are required and may reduce quality of the library. A circular or a linear 
expression systems can be recruited (Fennell et al., 2010;Shimizu et al., 2001;Villemagne et 
al., 2006). To construct the linear library, all required DNA elements, as promotor, ribosomal 
binding site and poly T tail, are synthesized or copied and constructed with the desired gene 
library through PCR (Katzen et al., 2005;Shimizu et al., 2001) . In the linear expression 
system, the library can have a maximal size up to 1013 (Table 4) (Gronwall & Stahl, 
2009).When a linear expression system is recruited, the qualities of final PCR products 
should be well controlled. It is better for the library to be freshly constructed everytime the 
protein display is performed. The size of a library constructed with a circular expression 
system is much smaller for the genotype lost during construction, however, the library can 
be stably stored in a good condition after construction.  
5.3 Mass production and folding of proteins 
To screening possible funtions of a protein, it requires a large amount of the protein. The 
amount of proteins with a CSαβ motif in their native host is rare and to obtain eounght of the 
native proteins for assays requires a lot of raw materials. To produce recombinant proteins of a 
CSαβ motif in bacteria cells, the proteins have to be fused with a large tag to reduce their 
toxicity to bacteria. Protein folding is also another problem for apporpriately forming the 
disulphide bonds of a CSαβ motif. To overcome the problems, peptides with CSαβ motif can 
be fused with a thioredoxin tag and a cleavagable site is placed between the peptide and the 
tag. The recombinant proteins are expressed in E. Coli and purified. After the thioredoxin tag is 
cut off, the desired proteins are further purified. A simple method to cut off the thioredoxin 
tag is to place a acidohydrolysis site, -Asp-Pro-, between the peptide and the tag (Liu et al., 
2006). A large amount of reconbinant proteins can be obtained by following the procedures 
and the native properties and functions of the proteins are preserved. The acidohydrolysis 
process is not suitable for proteins with a CSαβ motif containing proline for the proteins would 
be unstable in a heat and acidic environment (Cunningham & O'Connor, 1997;LeBlanc & 
London, 1997;Wilce et al., 1998). To resolve the problem, an alternative enzyme cleavage site 
can be introduced to replace the acidohydrolysis site. 
5.4 Unpredictable biochemical function 
Enzyme inhibitory function and microbial killing ability are the two greatest advantages of 
peptide with a CSαβ motif. The conventional bacterial/fungal killing assay is time 
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consuming and it is possible for a performer to be exposed to pathogens during the 
operation. The peptides with a CSαβ motif have been shown to form pores on an artificial 
membrane, but the artificial membrane does not represent the membrane of different 
organisms. A new high throughput screening recruiting membrane of different pathogens 
will be a great help in resolving the problem (Yang & Lyu, 2008). 
Not simple as binding assay, enzymes act on specific substrates and it is extremely difficult 
to unify experimental conditions for a broad spectrum of enzymes. In vitro enzyme 
inhibitory assays are costly and unable to represent the actually physiological conditions. 
Computer aided drug screening methods have been established to screen drugs with small 
molecule weights that can fit into active sites of target proteins (Barrons, 2004;Weideman et 
al., 1999). Drug dynamics also can be in silico simulated (Sinek et al., 2009;Zunino et al., 
2009). An antibody can be as a simple binder and its binding targets usually are short 
fragments exposed to the surface of the proteins. The binding fragments are predicable for a 
huge amount of knowledge accumulated in the last several decades (Blythe & Flower, 
2005;Kulkarni-Kale et al., ;Odorico & Pellequer, 2003). Currently, we do not well understand 
the interface between peptides with a CSαβ motif and their targets. How functional loops 
access active sites of the targets is needed to be decrypted. We know too little about the 
scaffold and it is to difficult to engineer it. It is hard to develop an algorithm to predict the 
biochemical functions of the peptides with a CSαβ motif. For the complexity of protein-
protein interaction, it is a long way to screen peptide drugs in silico. 
6. Business issue 
To biopharma companies, protein engineering/evolution platforms must provide solutions 
to improve the throughput, safety, biodistribution, activity and frequency of dosing of 
designed protein, evading intellectual property issues and reducing manufacturing costs, 
especially in the late process of development and production stages. Intellectual property 
rights are definite issues, the intellectual property situations of antibodies are obscure as 
previously described. An alternative scaffold equips the same abilities as antibody does is a 
valuable prospect and desired to avoid the complex intellectual property landscape of 
antibody. A protein scaffold can access to a cardinal target and circumvent intellectual 
property issues that does not mean that it is necessarily a platform worth investing in. The 
successfully designed protein must equip an improved performance and provide solutions 
to the concerned points described above. 
7. Conclusion 
The knowledge about the scaffold is not enough to establish rules to predict its biochemical 
functions. There are still some technical limitations and the development of the scaffold is 
confined. Peptides with a CSαβ motif bear many excellent properties and can serve as an 
alternative protein scaffold for biomedical application. Natural products containing 
peptides with a CSαβ motif have been therapeutically used for hundreds of years. Some of 
the purified peptides are tested and have low toxicities to mammalian species. Prudential is 
needed when recruiting new proteins/peptides as treatments for diseases. The intellectual 
property situation of peptides with a CSαβ motif is not as complex as antibody, especially in 
biomedical application (Yang & Lyu, 2008). For its original expression in plant, the 
engineered proteins with medicinal effect can be expressed in transgenic crops and diseases 
www.intechopen.com
 Development and Engineering of CSαβ Motif for Biomedical Application 
 
645 
can be controlled through foods. To predict the biochemical functions of peptides with a 
CSαβ motif is difficult, some prediction tools have been developed to predict functions of 
protein from the primary structure, but how proteins interact with their counterparts has to 
be considered. Folding and post-translational modification of proteins has to be thought 
over. We believe that peptides with a CSαβ motif will be an alternative scaffold and can be 
widely applied in biomedical utilities. 
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